Anti-MAPT therapeutic antibody (Pre-made Tilavonemab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Tilavonemab (formerly C2N 8E12) is a humanised recombinant anti-human tau monoclonal antibody, being developed by AbbVie and C2N Diagnostics for the treatment of various neurological disorders including Alzheimer's disease.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-572-1mg	1mg	3090
GMP-Bios-ab-572-10mg	10mg	21890
GMP-Bios-ab-572-100mg	100mg	148000
GMP-Bios-ab-572-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Anti-MAPT therapeutic antibody (Pre-made Tilavonemab biosimilar,Whole mAb)
INN Name	Tilavonemab
Target	MAPT
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2018
Year Recommended	2019
Companies	AbbVie;C2N Diagnostics
Conditions Approved	na
Conditions Active	Alzheimer's disease;Progressive supranuclear palsy
Conditions Discontinued	na
Development Tech	na